TH287

TH287 is a potent and selective inhibitor of MTH1, with an IC50 of 0.8 nM. TH287 is highly selective towards MTH1, with no relevant inhibition of MTH2, NUDT5, NUDT12, NUDT14, NUDT16, dCTPase, dUTPase and ITPA at 100 μM. TH287 could act as a chemotherapeutic agent for cancer research[1].

Product Specifications

CAS Number

[1609960-30-6]

UNSPSC

12352005

Hazard Statement

H302, H318

Target

DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TH287.html

Purity

98.29

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC1=NC(C2=CC=CC(Cl)=C2Cl)=CC(NC)=N1

Molecular Formula

C11H10Cl2N4

Molecular Weight

269.13

Precautions

H302, H318

References & Citations

[1]Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508 (7495) :215-21.|[2]Saleh A, et, al. Development and validation of method for TH588 and TH287, potent MTH1 inhibitors and new anti-cancer agents, for pharmacokinetic studies in mice plasma. J Pharm Biomed Anal. 2015 Feb;104:1-11.